Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21651951 | 0.87 | MCHR1 (0.43) | ADORA2AHCRTR1HCRTR2HRH3ACACB | |
| SCHEMBL20152054 | 0.86 | HRH3 (0.48) | ADORA2AHRH3ACACBMCHR1PARP1 | |
| SCHEMBL20069361 | 0.82 | CHRM4 (0.45) | ADORA2AHCRTR1HCRTR2 | |
| SCHEMBL20147430 | 0.80 | HRH3 (0.52) | HCRTR1HCRTR2HRH3ACACB | |
| SCHEMBL20147443 | 0.78 | HCRTR1 (0.42) | HCRTR1HCRTR2ACACBMCHR1 | |
| SCHEMBL20909894 | 0.77 | HCRTR1 (0.45) | HCRTR1HCRTR2MCHR1 | |
| SCHEMBL20137745 | 0.76 | HCRTR1 (0.47) | HCRTR1HCRTR2ACACB | |
| SCHEMBL20137746 | 0.76 | HCRTR1 (0.47) | HCRTR1HCRTR2ACACB | |
| SCHEMBL3322308 | 0.75 | HRH3 (0.39) | HRH3 | |
| SCHEMBL17687849 | 0.75 | ADORA2A (0.42) | ADORA2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | ADORA2A 3535/4885HCRTR1 2257/4885HCRTR2 3543/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | ADORA2A 3535/4885HCRTR1 2257/4885HCRTR2 3543/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | ADORA2A 3535/4885HCRTR1 2257/4885HCRTR2 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.